A frequent reason for discontinuation of therapy is dry mouth, which is reported by as many as 80% of patients receiving the immediate-release formulation of oxybutynin (widely considered the ...

More than one in ten adults live with dry mouth and an estimated 7 million older adults have the condition. But many patients ...